Treatment efficacy and safety of low dose Seladelpar, a selective PPAR-delta agonist, in patients with primary biliary cholangitis: twelve-week interim analysis of an international, randomized, dose ranging, phase 2 study
HEPATOLOGY(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要